A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
Condition: SmallpoxInterventions: Biological: IMVAMUNE; Biological: IMVAMUNESponsor: Bavarian NordicCompleted - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials